Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FAM230H (Family with sequence similarity 230 member H) is classified as a long non-coding RNA (lncRNA)[5]. It does not code for a protein, and its biological function is not well-characterized in published literature. There is no evidence to suggest it acts as a receptor, enzyme, transporter, or other typical drug target type, nor is it generally referenced as a therapeutic target. It is annotated in genomic resources under alternative names such as AP000552.1. Due to its status as a lncRNA, it currently has no known roles in disease or as a biomarker, and there are no interacting drugs or described mechanisms of action. No evidence from reviewed sources suggests that the information is incorrect, though notable for drug discovery purposes is that this is not a canonical therapeutic target[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Family with sequence similarity 230 member H (FAM230H).